XLON
SN.
Market cap11bUSD
Mar 24, Last price
1,239.16GBP
Name
Smith & Nephew PLC
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Smith & Nephew plc is a global medical technology enterprise dedicated to the development, manufacturing, and worldwide commercialization of an extensive array of medical devices. Its product portfolio spans several key areas. In orthopedics, the company provides knee implants for replacement procedures, hip implants for joint reconstruction, and trauma and extremities products, including both internal and external fixation devices, crucial for stabilizing severe fractures and correcting deformities. For sports medicine, Smith & Nephew offers joint repair solutions tailored for surgeons. This includes specialized instruments, advanced technologies, and implants essential for minimally invasive joint surgeries, targeting soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. Additionally, the firm supplies arthroscopic enabling technologies that enhance surgical visualization and intervention within joints. This suite encompasses fluid management equipment for surgical access, high-definition cameras, digital imaging capture systems, scopes, light sources, and monitors. It also features radiofrequency, electromechanical, and mechanical tissue resection devices, alongside hand instruments for precise tissue removal. The company also provides dedicated ear, nose, and throat (ENT) solutions. Its Advanced Wound Management division delivers comprehensive solutions for the treatment and prevention of acute and chronic wounds, covering conditions like leg, diabetic, and pressure ulcers, burns, and post-operative wounds. This segment includes advanced wound bioactives, comprising biologics and other bioactive technologies for debridement, dermal repair, and regeneration. Regenerative medicine products, such as skin, bone graft, and articular cartilage substitutes, are also offered. Furthermore, Smith & Nephew provides advanced wound devices, including traditional and single-use negative pressure wound therapy systems, and hydrosurgery technology. Primarily serving healthcare providers globally, Smith & Nephew plc was founded in 1856 and is headquartered in Watford, United Kingdom.
Related entities
Subsidiaries (12)
PLUS ORTHOPEDICS HELLAS S.A.
SMITH & NEPHEW ASIA PACIFIC PTE. LIMITED
SMITH & NEPHEW ESN LIMITED
SMITH & NEPHEW GBS PRIVATE LIMITED
SMITH & NEPHEW HEALTHCARE PRIVATE LIMITED
SMITH & NEPHEW HELLAS S.A.
SMITH & NEPHEW MANUFACTURING AG
SMITH & NEPHEW OPERATIONS B.V.
SMITH & NEPHEW ORTHOPAEDICS AG
SMITH & NEPHEW UK LIMITED
SMITH & NEPHEW, INC.
T.J.SMITH AND NEPHEW,LIMITED
Key people
Simon Fraser
President - Advanced Wound Management · since 2019
Mark Gladwell
President - Global Operations and Global Business Services · since 2019
Skip Kiil
President - Orthopedics · since 2018
Vasant Padmanabhan
President - Research & Development · since 2016
Chief Legal and Compliance Officer · since 2018
Susan Swabey
Company Secretary · since 2009
Non-Executive Director · since 2020
Virginia Hilda Brunette Maxwell Bottomley
Non-Executive Independent Director · since 2012
Non-Executive Independent Director · since 2015
Non-Executive Independent Director · since 2017
Headquarters & legal address
BUILDING 5, CROXLEY PARK
HATTERS LANE
WATFORD, HRT WD18 8YE
GB
HATTERS LANE
WATFORD, HRT WD18 8YE
GB
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||